Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 292

1.

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.

Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmüller G, Subklewe M.

Leukemia. 2016 Feb;30(2):484-91. doi: 10.1038/leu.2015.214. Epub 2015 Aug 4.

PMID:
26239198
2.

A novel, nonanaphylactogenic, bispecific IgE-CD3 antibody eliminates IgE(+) B cells.

Kirak O, Riethmüller G.

J Allergy Clin Immunol. 2015 Sep;136(3):800-802.e3. doi: 10.1016/j.jaci.2015.02.017. Epub 2015 Mar 29. No abstract available.

PMID:
25825213
3.

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M.

Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548. Epub 2013 Dec 3.

4.

IgE knock-in mice suggest a role for high levels of IgE in basophil-mediated active systemic anaphylaxis.

Lübben W, Turqueti-Neves A, Okhrimenko A, Stöberl C, Schmidt V, Pfeffer K, Dehnert S, Wünsche S, Storsberg S, Paul S, Bauer S, Riethmüller G, Voehringer D, Yu P.

Eur J Immunol. 2013 May;43(5):1231-42. doi: 10.1002/eji.201242675. Epub 2013 Mar 27. Erratum in: Eur J Immunol. 2013 Apr;43(5):1389-90.

5.

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.

Topp MS, Gökbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, Neumann SA, Horst HA, Raff T, Viardot A, Stelljes M, Schaich M, Köhne-Volland R, Brüggemann M, Ottmann OG, Burmeister T, Baeuerle PA, Nagorsen D, Schmidt M, Einsele H, Riethmüller G, Kneba M, Hoelzer D, Kufer P, Bargou RC.

Blood. 2012 Dec 20;120(26):5185-7. doi: 10.1182/blood-2012-07-441030. Epub 2012 Sep 28.

6.

Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.

Riethmüller G.

Cancer Immun. 2012;12:12. Epub 2012 May 1. Review. No abstract available.

7.

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC.

J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.

PMID:
21576633
8.

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.

Münz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S, Lumsden J, Volkland J, Fagerberg J, Riethmüller G, Rüttinger D, Kufer P, Baeuerle PA, Raum T.

Cancer Cell Int. 2010 Nov 2;10:44. doi: 10.1186/1475-2867-10-44.

9.

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.

Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P.

Science. 2008 Aug 15;321(5891):974-7. doi: 10.1126/science.1158545.

10.

Systemic spread is an early step in breast cancer.

Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA.

Cancer Cell. 2008 Jan;13(1):58-68. doi: 10.1016/j.ccr.2007.12.003.

11.

A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer.

Mecklenburg I, Weckermann D, Zippelius A, Schoberth A, Petersen S, Prang N, Riethmüller G, Kufer P.

J Immunol Methods. 2007 Jun 30;323(2):180-93. Epub 2007 May 15.

PMID:
17540401
12.

Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.

Schreiber K, Rowley DA, Riethmüller G, Schreiber H.

Hematol Oncol Clin North Am. 2006 Jun;20(3):567-84. Review.

PMID:
16762725
13.

Preferential targeting of CD4-CCR5 complexes with bifunctional inhibitors: a novel approach to block HIV-1 infection.

Mack M, Pfirstinger J, Haas J, Nelson PJ, Kufer P, Riethmüller G, Schlöndorff D.

J Immunol. 2005 Dec 1;175(11):7586-93.

14.

Detection of melanoma antigen-A expression in sputum and bronchial lavage fluid of patients with lung cancer.

Mecklenburg I, Stratakis DF, Huber RM, Häussinger K, Morresi-Hauf A, Riethmüller G, Kufer P.

Chest. 2004 May;125(5 Suppl):164S-6S. No abstract available.

PMID:
15136490
15.

Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells.

Ulmer A, Schmidt-Kittler O, Fischer J, Ellwanger U, Rassner G, Riethmüller G, Fierlbeck G, Klein CA.

Clin Cancer Res. 2004 Jan 15;10(2):531-7.

16.

Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses.

Mocikat R, Braumüller H, Gumy A, Egeter O, Ziegler H, Reusch U, Bubeck A, Louis J, Mailhammer R, Riethmüller G, Koszinowski U, Röcken M.

Immunity. 2003 Oct;19(4):561-9.

17.

From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression.

Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7737-42. Epub 2003 Jun 13.

18.
19.

Limitations of the immunocytochemical detection of isolated tumor cells in frozen samples of bone marrow obtained from melanoma patients.

Schadendorf D, Dorn-Beineke A, Borelli S, Riethmuller G, Pantel K.

Exp Dermatol. 2003 Apr;12(2):165-71.

PMID:
12702145
20.

T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct.

Dreier T, Baeuerle PA, Fichtner I, Grün M, Schlereth B, Lorenczewski G, Kufer P, Lutterbüse R, Riethmüller G, Gjorstrup P, Bargou RC.

J Immunol. 2003 Apr 15;170(8):4397-402.

21.

Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer.

Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Riethmüller G.

Lancet. 2002 Aug 31;360(9334):683-9.

PMID:
12241875
22.

Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.

Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA.

Int J Cancer. 2002 Aug 20;100(6):690-7.

23.

In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.

Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmüller G, Baeuerle PA, Dreier T.

Int J Cancer. 2002 Jul 1;100(1):101-10.

24.

Combined transcriptome and genome analysis of single micrometastatic cells.

Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, Wendler N, Passlick B, Huber RM, Schlimok G, Baeuerle PA, Riethmüller G.

Nat Biotechnol. 2002 Apr;20(4):387-92.

PMID:
11923846
25.

Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease.

Kufer P, Zippelius A, Lutterbüse R, Mecklenburg I, Enzmann T, Montag A, Weckermann D, Passlick B, Prang N, Reichardt P, Dugas M, Köllermann MW, Pantel K, Riethmüller G.

Cancer Res. 2002 Jan 1;62(1):251-61.

26.
27.

Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value.

Weckermann D, Müller P, Wawroschek F, Harzmann R, Riethmüller G, Schlimok G.

J Urol. 2001 Aug;166(2):699-703.

PMID:
11458120
28.

[Monoclonal antibodies: development and clinical prospects].

Borchmann P, Riethmüller G, Engert A.

Internist (Berl). 2001 Jun;42(6):803-4, 807-14. Review. German. No abstract available.

PMID:
11449627
29.
30.
31.

ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.

Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmüller G, Pantel K.

Cancer Res. 2001 Mar 1;61(5):1890-5.

32.

Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions.

Balzar M, Briaire-de Bruijn IH, Rees-Bakker HA, Prins FA, Helfrich W, de Leij L, Riethmüller G, Alberti S, Warnaar SO, Fleuren GJ, Litvinov SV.

Mol Cell Biol. 2001 Apr;21(7):2570-80.

33.

Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse.

Braun S, Schindlbeck C, Hepp F, Janni W, Kentenich C, Riethmüller G, Pantel K.

J Clin Oncol. 2001 Jan 15;19(2):368-75.

PMID:
11208828
34.

Analytical variables of reverse transcription-polymerase chain reaction-based detection of disseminated prostate cancer cells.

Zippelius A, Lutterbüse R, Riethmüller G, Pantel K.

Clin Cancer Res. 2000 Jul;6(7):2741-50.

36.

M-DC8+ leukocytes--a novel human dendritic cell population.

Schäkel K, Poppe C, Mayer E, Federle C, Riethmüller G, Rieber EP.

Pathobiology. 1999;67(5-6):287-90.

PMID:
10725804
37.

A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.

Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dörken B, Bargou RC.

Blood. 2000 Mar 15;95(6):2098-103.

38.

Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.

Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmüller G, Schlimok G.

N Engl J Med. 2000 Feb 24;342(8):525-33. Erratum in: N Engl J Med 2000 Jul 27;343(4):308.

39.

Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.

Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmüller G, Willgeroth F, Sommer HL.

Clin Cancer Res. 1999 Dec;5(12):3999-4004.

40.

Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors.

Weckermann D, Müller P, Wawroschek F, Krawczak G, Riethmüller G, Schlimok G.

J Clin Oncol. 1999 Nov;17(11):3438-43.

PMID:
10550139
41.

Hunting down the seminal cells of clinical metastases.

Riethmüller G, Klein CA, Pantel K.

Immunol Today. 1999 Jul;20(7):294-6. No abstract available.

PMID:
10475677
42.

p53 gene mutations are not required for early dissemination of cancer cells.

Offner S, Schmaus W, Witter K, Baretton GB, Schlimok G, Passlick B, Riethmüller G, Pantel K.

Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6942-6.

43.

Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells.

Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmüller G.

Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4494-9.

44.
45.
46.

Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.

Braun S, Müller M, Hepp F, Schlimok G, Riethmüller G, Pantel K.

J Natl Cancer Inst. 1998 Jul 15;90(14):1099-101. No abstract available.

PMID:
9672259
47.

Diagnosis and therapeutic relevance of micrometastases.

Holz E, Pantel K, Riethmüller G.

Recent Results Cancer Res. 1998;146:214-8. Review.

PMID:
9670262
48.

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R.

J Clin Oncol. 1998 May;16(5):1788-94.

PMID:
9586892
49.

Lack of protection from HIV infection by the mutant HIV coreceptor CCR5 in intravenously HIV infected hemophilia patients.

Malo A, Rommel F, Bogner J, Gruber R, Schramm W, Goebel FD, Riethmüller G, Wank R.

Immunobiology. 1998 Feb;198(4):485-8.

PMID:
9562872
50.

Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer.

Pantel K, Passlick B, Vogt J, Stosiek P, Angstwurm M, Seen-Hibler R, Häussinger K, Thetter O, Izbicki JR, Riethmüller G.

J Clin Oncol. 1998 Apr;16(4):1407-13.

PMID:
9552044

Supplemental Content

Loading ...
Support Center